627 research outputs found


    Get PDF
    Desvenlafaxine  succinate (pristiq) is an important non-hormonal drug used in the treatment of major depressive disorder and problems associated with menopause.This article summarizes the synthesis and investigation of new polymorphic form of Desmethylvenlafaxine. The new polymorph has been compared with the old polymorph using XRD, DSC, FTIR, SEM and HPLC techniques. Three prominent reflections with higher intensities lying at 20.3, 13.1 and 15.8 have been noted in the XRD measurements for the new polymorph. Higher intensity (XRD) peaks for the new polymorph indicates good crystalline quality. FTIR spectra shows close match between the polymorphs. DSC measurements show enhanced thermal stability for the new polymorph. Higher purity is indicated by the HPLC studies.Key words: desvenlafaxine, polymorphism, structure, crystalline, purit

    New Antidepressant Medication: Benefits Versus Adverse Effects

    Get PDF
    Depression [major depressive disorder (MDD)] is a mood disturbance of multifactorial origin, associated with high rates of morbidity and mortality, lack of work productivity, adverse health behaviors, and increased healthcare expenses. MDD is a leading cause of suicide, and it affects the prognosis of chronic conditions (heart diseases, diabetes, and cancer, among others). Current pharmacological treatment for MDD covers different classes of drugs, including tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants. The aim of this chapter is to review the literature, highlight the side effects of newer antidepressants, and especially point out the most important aspects of the latest agents approved for the treatment of MDD in adults: desvenlafaxine, levomilnacipran, vilazodone, and vortioxetine. Desvenlafaxine is a SNRI and the primary active metabolite of venlafaxine; also a SNRI, levomilnacipran is an enantiomer of the racemate milnacipran. Vilazodone and vortioxetine are multimodal antidepressants, which combine SSRI activity with additional receptor activity. Although they have proven efficacy in treating MDD and are being investigated for other possible indications, further detailed clinical trials are needed to establish their pharmaco-toxicological profile, following prolonged administration in patients who may suffer from various comorbidities

    Ansofaxine Hydrochloride

    Get PDF
    Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor that inhibits serotonin, dopamine and norepinephrine reuptake. This novel triple reuptake inhibitor is a carboxylic acid ester prodrug of desvenlafaxine. It is currently under development for the treatment of major depressive disorder - a frequent and heterogeneous disorder induced by a complex pattern of genetic, epigenetic, developmental, and environmental factors

    Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes : a systematic qualitative review

    Get PDF
    Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)—currently a common choice for non-hormonal treatment of menopausal HFs.Publisher PDFPeer reviewe

    Clinically Relevant Interactions between Newer Antidepressants and Second-Generation Antipsychotics

    Get PDF
    INTRODUCTION: Combinations of newer antidepressants and second-generation antipsychotics (SGAs) are frequently used by clinicians. Pharmacokinetic drug interaction (PK DI) and poorly understood pharmacodynamic (PD) drug interaction (PD DI) can occur between them. AREAS COVERED: This paper comprehensively reviews PD DI and PK DI studies. EXPERT OPINION: More PK DI studies are needed to better establish dose correction factors after adding fluoxetine and paroxetine to aripiprazole, iloperidone and risperidone. Further PK DI studies and case reports are also needed to better establish the need for dose correction factors after adding i) fluoxetine to clozapine, lurasidone, quetiapine and olanzapine; ii) paroxetine to olanzapine; iii) fluvoxamine to asenapine, aripiprazole, iloperidone, lurasidone, olanzapine, quetiapine and risperidone; iv) high sertraline doses to aripiprazole, clozapine, iloperidone and risperidone: v) bupropion and duloxetine to aripiprazole, clozapine, iloperidone and risperidone; and vi) asenapine to paroxetine and venlafaxine. Possible beneficial PD DI effects occur after adding SGAs to newer antidepressants for treatment-resistant major depressive and obsessive-compulsive disorders. The lack of studies combining newer antidepressants and SGAs in psychotic depression is worrisome. PD DIs between newer antidepressants and SGAs may be more likely for mirtazapine and bupropion. Adding selective serotonin reuptake inhibitors and SGAs may increase QTc interval and may very rarely contribute to torsades de pointes
    • …